Skip to content

Study · In vitro (cell-free) · 2007

1 result

Mapping the ADF/cofilin binding site on monomeric actin by competitive cross-linking and peptide array: evidence for a second binding site on monomeric actin.

Mannherz HG, Ballweber E, Galla M, Villard S, Granier C, Steegborn C, Schmidtmann A, Jaquet K, Pope B, Weeds AG

Journal of molecular biology15 Dec 2006Cited by 34 (Europe PMC)

PMID17196218 (opens in a new tab)DOI10.1016/j.jmb.2006.11.100 (opens in a new tab)PepBankPUB-17196218
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In cross-linking experiments with G-actin, thymosin beta4 inhibited binding by ADF or cofilin.

    In plain wordsIn lab tests with purified proteins, thymosin beta4 blocked ADF or cofilin from binding to actin.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInhibition of ADF/cofilin binding to G-actin
    Study

    n: not reported in source

    Cross-linking with ADP-ribosylated actin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both vitamin D-binding protein and thymosin beta4 inhibit binding by ADF or cofilin, while cofilin or ADF and DNase I bind simultaneously.
    1 context sentence
    Summary · context
    The binding sites for actin depolymerising factor (ADF) and cofilin on G-actin have been mapped by competitive chemical cross-linking using deoxyribonuclease I (DNase I), gelsolin segment 1 (G1), thymosin beta4 (Tbeta4), and vitamin D-binding protein (DbP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.